Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Epitel, Prapela Are First To Win READI-Home Spots As FDA Eyes Home-Care Devices

28 August 2026 · By · Wire by Fusion42

Published

28 August 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at insights.citeline.com →

◆ Verified

Fusion42 · 28 August 2026 · Fusion42 review

Epitel and Prapela became the first companies to earn spots in the FDA's READI-Home pilot programme, marking initial regulatory moves focused on home-care medical devices in the United States.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

FDA's pilot creates a rare market opening in home-care devices now regulated for safety and effectiveness, and that gap is your immediate entry point if you serve patients outside hospitals.

◆ Coverage

1 source · 28 Aug 2026

◆ Related on Wire

◆ Topics

MedtechFDAhome-caremedical-devicesregulatory-pilotmedtech